Down-regulation of RPS9 Inhibits Osteosarcoma Cell Growth through Inactivation of MAPK Signaling Pathway

Cheng, Dongdong; Zhu, Bin; Li, Shijie; Tan, Yuan; Yang, Qingcheng; Fan, Cunyi

doi:10.7150/jca.19130

Cited by 26 publications

(25 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Additionally, reduced expression of MLL3 is reported in breast tumors and gastric cancer [43, 44]. Ribosomal Protein S9 ( RPS9 ) is one of the first proteins that directly bind to the 18S rRNA and plays a crucial role in ribosome biogenesis [45–47]. Inhibition of RPS9 activates p53 activity, it is suggested to be an efficient method to induce apoptosis in tumor cells [48].…”

Section: Discussionmentioning

confidence: 99%

Events of alternative splicing in head and neck cancer via RNA sequencing – an update

Sharma

Nandan²,

Singh

et al. 2019

BMC Genomics

View full text Add to dashboard Cite

Background Alternative splicing (AS) is a regulatory mechanism used to create many forms of mature messengers RNAs (mRNAs) from the same gene. Sequencing of RNA (RNA-Seq) is an advanced technology, which has been utilized by different studies to find AS mechanisms in head and neck cancer (HNC). Hitherto, there is no available review that could inform us of the major findings from these studies. Hence, we aim to perform a systematic literature search following PRISMA guidelines to study AS events in HNC identified through RNA-Seq studies. Results A total of five records were identified that utilized RNA-Seq data for identifying AS events in HNC. Five software was used in these records to identify AS events. Two genes influenced by AS i.e. MLL3 and RPS9 were found to be common in 4 out of 5 records. Likewise, 38 genes were identified to be similar in at least 3 records. Conclusions Alternative splicing in HNC is a multifaceted regulatory mechanism of gene expression. It can be studied via RNA-Seq using different bioinformatics tools. Genes MLL3 , as well as RPS9, were repeatedly found to be associated with HNC, however needs further functional validation. Electronic supplementary material The online version of this article (10.1186/s12864-019-5794-y) contains supplementary material, which is available to authorized users.

show abstract

Section: Discussionmentioning

confidence: 99%

Events of alternative splicing in head and neck cancer via RNA sequencing – an update

Sharma

Nandan²,

Singh

et al. 2019

BMC Genomics

View full text Add to dashboard Cite

show abstract

“…The MAPK pathway has also been demonstrated to have a key role in tumor cell survival and migration ( 34 ). Several drugs targeting the MAPK pathway have been reported to inhibit cell proliferation in osteosarcoma ( 35 ). The present study indicated that the Akt and MAPK pathways were activated in the drug-resistant cell line, and their activation was significantly inhibited following knockdown of TGM2.…”

Section: Discussionmentioning

confidence: 99%

TGM2 knockdown reverses cisplatin chemoresistance in osteosarcoma

Cai

Fu-gui

et al. 2018

Int J Mol Med

View full text Add to dashboard Cite

In the past decades, chemotherapy has resulted in improved outcomes for patients with osteosarcoma. However, resistance to chemotherapy often leads to poor prognoses. Cisplatin is a standard drug for osteosarcoma therapy, and chemoresistance to cisplatin in osteosarcoma limits the effectiveness of chemotherapy drugs. Transglutaminase 2 (TGM2) is a member of the transglutaminase family, and it is reported to be associated with chemoresistance in various types of cancer. The present study aimed to investigate the function of TGM2 in regulating chemosensitivity of osteosarcoma cells to cisplatin. For in vitro experiments, a cisplatin-resistant osteosarcoma cell line (Saos2-CIS-R) was established, and TGM2 was demonstrated to be upregulated in the resistant Saos2-CIS-R cells compared with the normal Saos2 cells. The present study also revealed that TGM2 was associated with chemoresistance to cisplatin in osteosarcoma cells, and knockdown of TGM2 enhanced their chemosensitivity. In addition, TGM2 was demonstrated to affect the chemosensitivity of osteosarcoma cells via regulation of the activation of mitogen-activated protein kinase and AKT serine/threonine kinase pathways. Expression of BCL2 apoptosis regulator, BCL2 associated X and caspase-3 was also involved in chemoresistance development in osteosarcoma. For in vivo experiments, a mouse model was used to detect that the cisplatin sensitivity of Saos2-CIS-R cells was reversed following TGM2 knockdown. Taken together, the present data suggested a potentially important role for TGM2 in the regulation of osteosarcoma chemosensitivity. TGM2 might therefore serve as a therapeutic target for osteosarcoma.

show abstract

“…Micrometer‐thick Ag‐PVA, Au‐PVA, Pt‐PVA, Pd‐PVA and Ag−Au‐PVA films have shown optical limiting effects comparable to colloidal solutions with a path length of several millimeters ,,,,, Pattern formation: Electron beam lithography has been used to generate nanoscale patterns through the in situ generation of Ag nanoparticles in a PVA thin film; such composites are likely to be of interest in plasmonic devices. Random laser: In situ fabricated Ag‐PVA thin films containing rhodamine 6G has been shown to be a highly cost‐effective design of a random laser with coherent feedback; recently, a white random laser has also been demonstrated Microwave absorber: Ag‐PVA thin film with ∼10% Ag content exhibits appreciable microwave absorption in the 8–12 GHz range …”

Section: Polymer – Metal/bimetal/semiconductor Nanocomposite Thin Filmsmentioning

confidence: 99%

“…Random laser: In situ fabricated Ag‐PVA thin films containing rhodamine 6G has been shown to be a highly cost‐effective design of a random laser with coherent feedback; recently, a white random laser has also been demonstrated …”

Section: Polymer – Metal/bimetal/semiconductor Nanocomposite Thin Filmsmentioning

confidence: 99%

‘Dip Catalysts’ Based on Polymer‐Metal Nanocomposite Thin Films: Combining Soft‐Chemical Fabrication with Efficient Application and Monitoring

2018

View full text Add to dashboard Cite

Nanocatalysts can potentially harmonize the advantages of homogeneous and heterogeneous catalysts, provided they are sequestered in a suitable host matrix that not only enables convenient introduction into repeated reaction cycles, but also allows facile access for the reaction system. Polymer-metal/semiconductor nanocomposite thin films fabricated through an in situ protocol offer a promising solution involving eco-friendly synthesis and sustainable application. Salient features of the approach include (i) the simple, softchemical fabrication methodology that also allows real-time observation of the catalyst formation, (ii) efficient nano-catalyst action through the facile movement of the reactants and products to and from the catalyst site enabled by the swelling of the polymer matrix, and (iii) realization of the 'dip catalyst' concept that emphasizes the ease of insertion and retrieval of the thin film into and from the reaction system, coupled with the feasibility of effective catalyst monitoring through multiple uses. An overview of the nanocomposite thin film fabrication, types of nanostructures that have been reported in this context, deployment of the thin film 'dip catalysts' in several reactions, and emerging new directions in the field and open problems are presented.[a] U.

show abstract

Down-regulation of RPS9 Inhibits Osteosarcoma Cell Growth through Inactivation of MAPK Signaling Pathway

Cited by 26 publications

References 34 publications

Events of alternative splicing in head and neck cancer via RNA sequencing – an update

Events of alternative splicing in head and neck cancer via RNA sequencing – an update

TGM2 knockdown reverses cisplatin chemoresistance in osteosarcoma

‘Dip Catalysts’ Based on Polymer‐Metal Nanocomposite Thin Films: Combining Soft‐Chemical Fabrication with Efficient Application and Monitoring

Contact Info

Product

Resources

About